Skip to main content
Premium Trial:

Request an Annual Quote

By Oxford BioDynamics

Q&A: How a Noninvasive Blood Test is Changing Immunotherapy Treatment

The noninvasive test evaluates eight 3D genomic markers and is the only test that returns a binary result to the ordering physician with high accuracy: “low probability” or “high probability” of response to an ICI.

By VolitionRx

First CE-Marked Assay to Aid in NETosis-Associated Disease Evaluation Has Applications in COVID-19, Sepsis Monitoring

The Nu.Q NETs test is the first approved clinical assay to assess disease severity by quantifying circulating nucleosomes which make up plasma neutrophil extracellular traps, or NETs — snares of DNA expelled by neutrophils to trap and kill invading pathogens.

By Seegene Inc

Seegene Seeks to Curb Oncoming COVID-19 Surges with Routine Syndromic PCR Testing

Seegene has joined hands with LabHouse, a testing center in Vietnam, to launch the In-Life PCR campaign for ride-hailing drivers in Ho Chi Minh and Hanoi, and the company is in talks with testing labs in countries around the world to launch the campaign in more regions,

By PreAnalytix

IVDR-Compliant Liquid Biopsy Preanalytical Workflow Can Address Challenges in Clinical ccfDNA Analysis

Diagnostic laboratories in the EU can utilize the IVDR-compliant PAXgene Blood ccfDNA workflow in a variety of noninvasive ccfDNA-based diagnostic applications.

By F. Hoffmann-La Roche Ltd.

New TMB Recommendations Help to Guide Treatment Decisions in Oncology

Recent recommendations from the ESMO Precision Medicine Working Group and National Comprehensive Cancer Network, coupled with US Food and Drug Administration review and approval, have highlighted the use of tumor mutational burden testing in clinical practice for a number of different tumor types.